The 'Spin' in Spin-off: Tricky if Not Handled, Myriad Finds
By Randy Osborne
Monday, July 6, 2009
The lukewarm day-one reception on Wall Street last week for Myriad Genetics Inc.'s spin-off of Myriad Pharmaceuticals Inc. foretells neither the success of the new firm nor of similar models tried by other companies, but it does sharpen the points on some of the questions raised by those earlier attempts - and shows what a difference timing can make.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.